Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 6/2011

01-12-2011 | Overactive Bladder (Gopal Badlani, Section Editor)

Bladder Dysfunction in Patients with Diabetes

Authors: Christopher S. Gomez, Prashanth Kanagarajah, Angelo E. Gousse

Published in: Current Urology Reports | Issue 6/2011

Login to get access

Abstract

With diabetes mellitus (DM) reaching epidemic proportions, the identification of voiding dysfunction as a common and burdensome complication of this disease is critical. Research into diabetic voiding dysfunction significantly lags behind other complications of DM, such as retinopathy and nephropathy. Recent studies have revealed that DM predisposes patients to a wide range of lower urinary tract dysfunction, from the classic diabetic cystopathy of incomplete emptying to urgency incontinence. In this review, we discuss the current concepts of diabetic voiding dysfunction with a critical analysis of the available evidence.
Literature
1.
Centers for Disease Control and Prevention. 2011. Atlanta, G.: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011, 2011.
2.
3.
Liu G, Daneshgari F. Alterations in neurogenically mediated contractile responses of urinary bladder in rats with diabetes. Am J Physiol Renal Physiol. 2005;288:F1220.PubMedCrossRef
4.
Daneshgari F, Huang X, Liu G, et al. Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1728.PubMedCrossRef
5.
• Daneshgari F, Leiter EH, Liu G., et al.: Animal models of diabetic uropathy. J Urol. 2009;182:S8. This is an excellent review of animal models used to study diabetic uropathy. PubMedCrossRef
6.
7.
Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res. 2000;1:89.PubMedCrossRef
8.
Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med. 1976;119:85.PubMedCrossRef
9.
10.
Hill SR, Fayyad AM, Jones GR. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol Urodyn. 2008;27:362.PubMedCrossRef
11.
Lee WC, Wu HP, Tai TY, et al. Investigation of urodynamic characteristics and bladder sensory function in the early stages of diabetic bladder dysfunction in women with type 2 diabetes. J Urol. 2009;181:198.PubMedCrossRef
12.
Sasaki K, Chancellor MB, Phelan MW, et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. J Urol. 2002;168:1259.PubMedCrossRef
13.
Hellweg R, Raivich G, Hartung HD, et al. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol. 1994;130:24.PubMedCrossRef
14.
Sasaki K, Chancellor MB, Goins WF, et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes. 2004;53:2723.PubMedCrossRef
15.
Yamaguchi C, Sakakibara R, Uchiyama T, et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn. 2007;26:807.PubMedCrossRef
16.
Saito M, Okada S, Kazuyama E, et al. Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto-Kakizaki diabetic rat bladders. J Urol. 2008;180:2701.PubMedCrossRef
17.
Yoshimura N, Chancellor MB, Andersson KE, et al. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 2005;95:733.PubMedCrossRef
18.
Sun Y, Chai TC. Role of purinergic signaling in voiding dysfunction. Curr Bladder Dysfunct Rep. 2010;5:219.PubMedCrossRef
19.
Poladia DP, Bauer JA. Early cell-specific changes in nitric oxide synthases, reactive nitrogen species formation, and ubiquitinylation during diabetes-related bladder remodeling. Diabetes Metab Res Rev. 2003;19:313.PubMedCrossRef
20.
Torimoto K, Fraser MO, Hirao Y, et al. Urethral dysfunction in diabetic rats. J Urol. 2004;171:1959.PubMedCrossRef
21.
Yang Z, Dolber PC, Fraser MO. Diabetic urethropathy compounds the effects of diabetic cystopathy. J Urol. 2007;178:2213.PubMedCrossRef
22.
Pinna C, Zanardo R, Puglisi L. Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats. Eur J Pharmacol. 2000;388:267.PubMedCrossRef
23.
Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol. 1995;153:342.PubMedCrossRef
24.
Lifford KL, Curhan GC, Hu FB, et al. Type 2 diabetes mellitus and risk of developing urinary incontinence. J Am Geriatr Soc. 2005;53:1851.PubMedCrossRef
25.
Lee WC, Wu HP, Tai TY, et al. Effects of diabetes on female voiding behavior. J Urol. 2004;172:989.PubMedCrossRef
26.
Lee WC, Wu CC, Wu HP, et al. Lower urinary tract symptoms and uroflowmetry in women with type 2 diabetes mellitus with and without bladder dysfunction. Urology. 2007;69:685.PubMedCrossRef
27.
Fayyad AM, Hill SR, Jones G. Urine production and bladder diary measurements in women with type 2 diabetes mellitus and their relation to lower urinary tract symptoms and voiding dysfunction. Neurourol Urodyn. 2010;29:354.PubMed
28.
Nakayama H, Jorgensen HS, Pedersen PM, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke. 1997;28:58.PubMedCrossRef
29.
Brown JS, Vittinghoff E, Lin F, et al. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001–2002. Diabetes Care. 2006;29:1307.PubMedCrossRef
30.
Frimodt-Moller C. Diabetic cystopathy. A review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan Med Bull. 1978;25:49.PubMed
31.
Ho CH, Tai HC, Yu HJ. Urodynamic findings in female diabetic patients with and without overactive bladder symptoms. Neurourol Urodyn. 2010;29:424.PubMed
32.
Mumtaz FH, Sullivan ME, Thompson CS, et al. Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy. J Urol. 1999;162:558.PubMedCrossRef
33.
Kitami K. Vesicourethral dysfunction of diabetic patients. Nippon Hinyokika Gakkai Zasshi. 1991;82:1074.PubMed
34.
Rohrmann S, Platz EA, Giovannucci E. Life-style and benign prostatic hyperplasia in older men: what do we know? J Mens Health Gend. 2005;2:230.CrossRef
35.
Sarma AV, Parsons JK, McVary K, et al. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms–what do we know? J Urol. 2009;182:S32.PubMedCrossRef
36.
Michel MC, Mehlburger L, Schumacher H, et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000;163:1725.PubMedCrossRef
37.
Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562.PubMedCrossRef
38.
Burke JP, Jacobson DJ, McGree ME, et al. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. Urology. 2006;67:22.PubMedCrossRef
39.
Chokkalingam AP, Gao YT, Deng J, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 2002;52:98.PubMedCrossRef
40.
Sidney S, Quesenberry Jr C, Sadler MC, et al. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology. 1991;38:13.PubMedCrossRef
41.
Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol. 2009;182:S51.PubMedCrossRef
42.
Boyko EJ, Fihn SD, Scholes D, et al. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161:557.PubMed
43.
Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281.PubMedCrossRef
44.
Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510.PubMedCrossRef
45.
Harding GK, Zhanel GG, Nicolle LE, et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347:1576.PubMedCrossRef
46.
Van Den Eeden SK, Sarma AV, Rutledge BN, et al. Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care. 2009;32:664.CrossRef
47.
• Daniels DH, Powell CR, Braasch MR., et al. Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction. Neurourol Urodyn. 2010;29:578. This article shows evidence that sacral neuromodulation is as effective in diabetic versus nondiabetic patients.PubMed
48.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029.PubMedCrossRef
49.
Ustuner MC, Kabay S, Ozden H, et al. The protective effects of vitamin E on urinary bladder apoptosis and oxidative stress in streptozotocin-induced diabetic rats. Urology. 2010;75:902.PubMedCrossRef
50.
Saito M, Kinoshita Y, Satoh I, et al. Ability of cyclohexenonic long-chain fatty alcohol to reverse diabetes-induced cystopathy in the rat. Eur Urol. 2007;51:479.PubMedCrossRef
Metadata
Title
Bladder Dysfunction in Patients with Diabetes
Authors
Christopher S. Gomez
Prashanth Kanagarajah
Angelo E. Gousse
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 6/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-011-0214-0

Other articles of this Issue 6/2011

Current Urology Reports 6/2011 Go to the issue

Clinical Trial Report

The Scientific Rationale for Using Biomaterials in Stress Urinary Incontinence and Pelvic Organ Prolapse

Erectile Dysfunction (Thomas Lue, Section Editor)

Treatment of Peyronie’s Disease: 2012 Update

Overactive Bladder (Gopal Badlani, Section Editor)

Updates in the Management of the Overactive Bladder in Patients with Myelomeningocele

Overactive Bladder (Gopal Badlani, Section Editor)

Bladder Dysfunction and Parkinsonism: Current Pathophysiological Understanding and Management Strategies

Erectile Dysfunction (Tom Lue, Section Editor)

Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction

Overactive Bladder (Gopal Badlani, Section Editor)

Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management